When CLR was combined with clinical characteristics on prognosis in subgroup analysis, different clinical subgroups including age, gender, location, KRAS, and MMR subgroups were able to effectively differentiate prognostic outcomes among CRC patients. This evidence concerns the gene KRAS and colorectal carcinoma.